OnKure Therapeutics, Inc.

NasdaqGM:OKUR Stock Report

Market Cap: US$171.7m

OnKure Therapeutics Management

Management criteria checks 4/4

OnKure Therapeutics' CEO is Nick Saccomano, appointed in Sep 2023, has a tenure of 2.75 years. total yearly compensation is $1.47M, comprised of 40.9% salary and 59.1% bonuses, including company stock and options. directly owns 0.018% of the company’s shares, worth $31.16K. The average tenure of the management team and the board of directors is 2.3 years and 3.5 years respectively.

Key information

Nick Saccomano

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage40.87%
CEO tenure2.8yrs
CEO ownership0.02%
Management average tenure2.3yrs
Board average tenure3.5yrs

Recent management updates

Recent updates

Analysis Article • Jul 23

Is OnKure Therapeutics (NASDAQ:OKUR) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Mar 29

We're Keeping An Eye On OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 24

OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond

Summary Initial OnKure Therapeutics, Inc. data from the phase 1 PIKture-01 study, using OKI-219 for the treatment of patients with PI3Ka-H1047R breast cancer and solid tumors, is expected in Q4 of 2024. OKI-219 has 80X fold improved selectivity PI3K-a targeting versus wild-type PI3K-a, potentially allowing for higher dosing and reducing unwanted off-target effects. The merger with Reneo Pharmaceuticals and $65 million private placement boosts OnKure's cash to $139 million, funding operations into Q4 2026. Significant market opportunity exists with 15% of breast cancer patients expressing the PI3Ka-H1047R mutation, and the company aims to outperform competitors with greater selectivity of OKI-219. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Nick Saccomano's remuneration changed compared to OnKure Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$59m

Dec 31 2025US$1mUS$600k

-US$60m

Sep 30 2025n/an/a

-US$63m

Jun 30 2025n/an/a

-US$60m

Mar 31 2025n/an/a

-US$59m

Dec 31 2024US$10mUS$462k

-US$53m

Sep 30 2024n/an/a

-US$45m

Jun 30 2024n/an/a

-US$42m

Mar 31 2024n/an/a

-US$36m

Dec 31 2023US$346kUS$68k

-US$35m

Compensation vs Market: Nick's total compensation ($USD1.47M) is about average for companies of similar size in the US market ($USD1.64M).

Compensation vs Earnings: Nick's compensation has been consistent with company performance over the past year.

CEO

Nick Saccomano (67 yo)

2.8yrs
Tenure
US$1,467,934
Compensation

Dr. Nicholas A. Saccomano, Ph D., also known as Nick, is Scientific Advisor of Engine Biosciences Pte. Ltd.He serves as Chief Executive Officer at OnKure Therapeutics, Inc. from September 2023 and is its...

Leadership Team

NamePositionTenureCompensationOwnership
Nicholas Saccomano
President2.8yrsUS$1.47m0.018%
$ 31.2k
Jason Leverone
Chief Financial Officer4.4yrsUS$896.17k0.029%
$ 50.6k
Isaac Manke
Senior VP of Business Development & Directorless than a yearUS$76.79k0.051%
$ 87.5k
Samuel Agresta
Chief Medical Officer2.3yrsUS$851.73k0%
$ 0
Dylan Hartley
Chief Scientific Officer1.9yrsno data0%
$ 0
Rogan Nunn
General Counsel & Secretary2yrsno datano data
James Blake
Senior Vice President of Computational Drug Discovery4.9yrsno datano data
Kevin Litwiler
Senior Vice President of DMPK & Clinical Pharmacology4yrsno datano data
Mark Boys
Senior Vice President of Discovery Chemistryno datano datano data
Roberta Alton
Senior Vice President of Clinical Operations1.3yrsno datano data
2.3yrs
Average Tenure
53yo
Average Age

Experienced Management: OKUR's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Nicholas Saccomano
President5.4yrsUS$1.47m0.018%
$ 31.2k
Isaac Manke
Senior VP of Business Development & Director5.3yrsUS$76.79k0.051%
$ 87.5k
Michael Grey
Non-Employee Director1.7yrsUS$56.29k0.23%
$ 394.5k
R. Carruthers
Independent Non-Employee Director5.3yrsUS$71.29k0%
$ 0
Edward Mathers
Independent Non-Employee Director1.7yrsUS$61.29k0.038%
$ 65.1k
Liam Ratcliffe
Independent Directorless than a yearno datano data
Andrew Phillips
Independent Non-Employee Chairman5.3yrsUS$103.79k0%
$ 0
Valerie Jansen
Independent Non-Employee Director1.7yrsUS$60.29k0%
$ 0
3.5yrs
Average Tenure
64.5yo
Average Age

Experienced Board: OKUR's board of directors are considered experienced (3.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/10 13:50
End of Day Share Price 2026/06/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

OnKure Therapeutics, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert BurnsH.C. Wainwright & Co.
Soumit RoyJonesTrading Institutional Services, LLC
Andrew BerensLeerink Partners LLC